This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
FE Babl , AM Regan & SI Pelton (1999) Abnormal body-fat distribution in HIV-1 infected children on antiretrovirals. Lancet 353, 1243–1244.
MJ Batterham , R Garsia & P Greenop (1999) Measurement of body composition in people with HIV/AIDS: a comparison of bioelectrical impedance and skinfold anthropometry with dual-energy x-ray absorptiometry. Journal of American Dietetic Association 99, 1109–1111.
MK Baum et al. (1998) Micronutrient status in relationship to mortality in HIV-1 disease. Nutrition Reviews 56, S135–S139.
G Behrens , H Schmidt & D Meyer (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351, 1958.
G Behrens , A Dejam , H Schmidt , HJ Belks , G Brabnt , T Korner , M Stoll & RE Schmidt (1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13, 63–70.
PM Bell & DR Hadden (1997) Metformin. Endocrinology and Metabolism Clinics of North America 26, 523–537.
J Berger , L Pall , C Hall , D Simpson , P Berry & R Dudley (1996) Oxandrolone in AIDS-wasting myopathy. AIDS 10, 1657–1662.
S Bhasin , T Storer , N Asbel-Sethi (1998) Effects of testosterone replacement with a nongenital transdermal system, androderm, in human immunodeficiency virus-infected men with low testosterone levels. Journal of Clinical Endocrinology and Metabolism 83, 3155–3162.
S Bhasin , T Storer & M Javanbakht (2000) Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. Journal of the American Medical Association 283, 763–770.
S Blanche , M Tardieu , P Rustin , A Slama , B Barret , G Firtion , N Ciraru-Vigneron , C Lacroix , N Rouzioux , L Mandelbrot , I Desguerre , A Rötig , MJ Mayaux & JF Delfraissy (1999) Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354, 1084–1089.
K Brinkman , JA Smeitink , JA Romijn & P Reiss (1999) Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy related lipodystrophy. Lancet 354, 1112–1115.
F Carbonnel , C Maslo & L Beaugerie (1998) Effect of indinavir on HIV-related wasting. AIDS 12, 1777–1784.
A Carr , K Samaras , DJ Chisholm & DA Cooper (1998a) Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet 351, 1881–1883.
A Carr , K Samaras , S Burton , M Law , J Freund , D Chrisholm & DA Cooper (1998b) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS 12, 51–58.
A Carr , K Samaras , A Thorisdottir , GR Kaufmann , DJ Chrisholm & DA Cooper (1999) Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia and diabetes mellitus: a cohort study. Lancet 353, 2093–2099.
A Carr , J Miller , M Law & DA Cooper (2000) A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, 25–32.
SA Danner , A Carr & JM Leonard (1995) A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. The New England Journal of Medicine 333, 1528–1533.
MP Dubé , DL Johnson & JS Currier (1997) Protease inhibitor-associated hyperglycemia. Lancet 350, 713–714.
KJ Ellis & SJ Bell (1999) Bioelectrical impedance methods in clinical research: a follow-up to the NIH Technology Assessment Conference. Nutrition 15, 874–880.
B Gallet , M Pullik & P Genet (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351, 1958–1959.
A Garg & SM Grundy (1990) Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. Journal of the American Medical Association 264, 723–726.
A Garg (1998) Dyslipoproteinemia and diabetes. Endocrinology and Metabolism Clinics of North America 27, 613–625.
S Grinspoon , C Corcoran & K Miller (1997) Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. Journal of Clinical Endocrinology and Metabolism 82, 1332–1337.
S Grinspoon , C Corcoran & H Askari (1998) Effects of androgen administration in men with AIDS wasting: a randomized, placebo-controlled trial. Annals of Internal Medicine 129, 18–26.
S Grinspoon , C Corcoran & D Rosenthal (1999) Quantitative assessment of cross-sectional muscle area, functional status and strength in men with the AIDS wasting syndrome. Journal of Clinical Endocrinology and Metabolism 84, 201–206.
C Grunfeld , DP Kotler & JK Shigenaga (1991) Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. American Journal of Medicine 90, 154–162.
C Grunfeld , M Pang & W Doerrler (1992b) Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Journal of Clinical Endocrinology and Metabolism 74, 1045–1052.
C Hadigan , C Corcoran , T Stanley , S Piecuch , A Klibanski & S Grinspoon (2000a) Fasting hyperinsulinemia in HIV-infected men: relationship to body composition, gonadal function and protease-inhibitor use. Journal of Clinical Endocrinology and Metabolism 85, 35–41.
C Hadigan , K Miller , C Corcoran , E Anderson , N Basgoz & S Grinspoon (1999) Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. Journal of Clinical Endocrinology and Metabolism 84, 1932–1937.
SM Haffner & H Miettinen (1997) Insulin resistance implications for type II diabetes mellitus and coronary heart disease. American Journal of Medicine 103, 152–162.
K Henry , H Melroe & J Huebsch (1998a) Severe premature coronary artery disease with protease inhibitors. Lancet 351, 1328.
K Henry , H Melroe & J Huebsch (1998b) Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352, 1031–1032.
JE Hokanson & MA Austin (1996) Plamas triglyceride level is a risk factor for cardiovascular disease independent of HDL cholesterol level: a meta-analysis of population-based prospective studies. Journal of Cardiovascular Risk 3, 213–219.
MJT Hommes , JA Romijn , E Endert , JKM Eeftinck-Schattenkenkerk & HP Sauerwein (1991) Insulin sensitivity and insulin clearance in human immunodeficiency virus infected men. Metabolism 40, 651.
CS Ireton-Jones et al. (1998) Evaluation of outcomes for patients with AIDS receiving home total parenteral nutrition. Nutrition 14, 731–735.
JC Lo , K Mulligan , VW Tai , H Algren & M Schambelan (1998) Buffalo hump in men with HIV 1 infection. Lancet 351, 867–870.
DC Macallan , C Noble & C Baldwin (1995) Energy expenditure and wasting in human imunodeficiency virus infection. New England Journal of Medicine 333, 83–88.
S Madge , S Kinloch-de-Loes , D Mercey , MA Johnson & IVD Weller (1999) Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 13, 735–737.
E Martinez , I Conget & L Lozano (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13, 805–810.
JC Melchior , C Chastang & P Gelas (1996) Efficacy of 2 month total parenteral nutrition in AIDS patients: a controlled randomized prospective trial. AIDS 10, 379–384.
JC Melchior , T Niyongabo & D Henzel (1999) Malnutrition and wasting, immunodepression, and chronic inflammation as independant predictors of survival in HIV-infected patients. Nutrition 15, 865–869.
C Mhiri , L Belec , B DiCostanza , A Georges & R Gherardi (1992) The slim disease in African patients with AIDS. Transactions of the Royal Society of Tropical Medicine and Hygiene 86, 303–306.
KD Miller , E Jones & JA Yanovski (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351, 871–875.
BA Mizock & JL Falk (1992) Lactic acidosis in critical illness. Critical Care Medicine 20, 80–93.
K Mulligan , C Grunfeld , M Hellerstein , RA Neese & M Schambelan (1993) Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immuodeficiency virus infection. Journal of Clinical Endocrinology and Metabolism 77, 956–962.
K Mulligan , C Grunfeld , VW Tai , H Algren , M Pang , DN Chernoff & M Schambelan (2000) Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. Journal of Acquired Immunodeficiency Syndrome 23, 35–43.
BL Nahlen , SY Chu , OC Nwanyanwu , RL Berkelman , SA Martinez & JV Rullan (1993) HIV wasting syndrome in the United States. AIDS 7, 183.
T Niyongabo , JC Melchior , D Henzel , O Bouchard & B Larouze (1999) Comparison of methods for assessing nutritional status in HIV-infected adults. Nutrition 15, 740–743.
M Oster , S Enders & S Samuels (1994) Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine 121, 400–408.
NI Paton , LR Castello-Branco (1999) Impact of tuberculosis on the body composition of HIV-infected men in Brazil. Journal of Acquired Immunodeficiency Syndrome 20, 265–271.
N Paton , PJ Newton & D Sharpstone (1999) Short-term growth hormone administration at the time of opportunistic infections in HIV-positive people. AIDS 13, 1995–2002.
D Periard , A Telenti & P Sudre (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100, 700–705.
JQ Purnell , A Zambon & H Knopp (2000) Effects of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14, 51–57.
R Roubenoff , A McDermott , L Weiss , T Heflin , GJ Cloutier , M Wood & S Gorbach (1999) Short-term progressive resistance training increases strenght and lean body mass in adults infected with human immunodeficiency virus. AIDS 13, 231–239.
T Saint-Marc , M Partisani , I Poizot-Martin , O Rouvière , F Bruno , R Avallaneda , JM Lang , JA Gastaut & JL Touraine (1999) A syndrome of peripheral fat wasting in patients receiving long-term nucleoside analogue therapy. AIDS 13, 1659–1667.
S Safrin & C Grunfeld (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13, 2493–2505.
M Schambelan , K Mulligan & C Grunfeld (1996) Recombinant human growth hormone in patients with HUV-associated wasting. Annals of Internal Medicine 125, 873–882.
J Shabert , C Winslow , J Lacey & D Wilmore (1999) Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized double-blind controlled trial. Nutrition 15, 860–864.
M Silva , P Skolnik & S Gorbach (1998) The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 12, 1645–1651.
A Strawford , T Barbieri & R Neese (1999) Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. Journal of Acquired ImmnunoDeficiency Syndrome and Human Retrovirology 20, 137–146.
U Süttmann , J Ockenga & O Selberg (1995) Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. Journal of Acquired Immunodeficiency Syndrome 8, 239.
D Vittecoq , L Escaut & JJ Monsuez (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351, 1959.
J Von Roenn , D Amstrong & D Kotler (1994) Megestrol acetate in patients with AIDS-related cachexia. Annals of Internal Medicine 121, 393–399.
R Walli , O Herfort , GM Michl , T Demant , H Jager , C Dieterle , Bogner , R Landgraf & FD Goebel (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 12, 167–173.
C Wanke , M Silva , T Knox , J Forrester , D Speigelman & S Gorbach (2000) Weight loss and wasting remain common complications in individuals infected with HIV in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 31, 803–805.
DA Wheeler , CL Givert & CA Launer (1998) Weight loss as a predictor of survival and disease progression in HIV infection. Journal of Acquired Immunodeficiency Syndrome and Human Retrovirology 18, 80–85.